-
The present situation and prospect of glioma immunotherapy.
Time of Update: 2020-10-07
results of the study Glioma immunotherapy strategies: Immuno-target inhibitors (ICBs): programmed cell death proteins (PD-1) and ligations (PD-L1), as well as cytotoxic T lymphocyte-related antigens 4 (CTLA-4) are the main effect factors that block the immune response in the inhibitory immune path path.
-
Total mitigation rate of 92%! FDA grants Gilead CD47 single anti-magrolimab breakthrough drug: Treatment of bone marrow growth syndrome!
Time of Update: 2020-10-07
September 16, 2020 // -- Gilead Sciences recently announced that the U.S. Food and Drug Administration (FDA) has granted magolimab Breakthrough Drug Qualification (BTD), the first anti-CD47 monoclonal antibody to treat newly diagnosed myeloid growth syndrome (MDS).
-
New drug for lymphoma! CD19 Targeted Antibody Drug Couple (ADC) loncastuximab tesirine (Lonca) is on the market in the U.S.!
Time of Update: 2020-10-06
recently, the company announced that it had filed a bio-product licensing application (BLA) with the U.S. Food and Drug Administration (FDA) for Loncastuximab tesirine (Lonca, formerly known as ADCT-402), a drug used to treat recurring or recurring diffuse large B-cell lymphoma (DLBCL).
-
Heavy! Mercadon Keytruda assisted therapy has removed high-risk stage III melanoma to reduce the risk of distant metastasis/death by 40%!
Time of Update: 2020-10-06
data show that after 3.5 years of follow-up, Keytruda assisted therapy reached a critical secondary endpoint of no-distance transfer lifetime (DMFS): Keytruda assisted therapy significantly reduced the risk of distant metastasis or death by 40% compared to placebos (HR=0.60; 95% CI:0.49-0.73, p.001).
-
Bladder cancer is heavy! Opdivo assists in the treatment of high-risk muscle-immersive urethra cancer (MIUC) Phase III clinical success!
Time of Update: 2020-10-06
September 25, 2020 // -- BMS recently announced positive results for the critical Phase 3 CheckMate-274 trial of the anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab, Navulyu monoantigen) assisted (postoperative) treatment of patients with high-risk, muscle-immersive urethra cancer (MIUC).
-
First-line treatment of renal cell carcinoma! Hundred-time U.S. immunology combination Opdivo and Yervoy efficacy significantly better than Sutent, 48-month survival rate of 50%!
Time of Update: 2020-10-06
September 18, 2020 // -- BMS recently presented Opdivo (Odivo, common name: nivolumab) at the 2020 Virtual Conference of the European Society of Medical Oncology (ESMO) The latest results of the First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma (RCC) Phase III CheckMate-214 study (4-year data) in a joint low-dose Yervoy (ipilimumab, ipilimumma) phase III.
-
Bladder cancer is heavy! Merck/Pfizer immunotherapy Bavencio first-line maintenance therapy significantly extends total survival: it will change clinical practice!
Time of Update: 2020-10-06
Bavencio, an immuno-oncology drug developed in collaboration with Pfizer and Merck, was approved by the FDA in May 2017 to treat patients with localized advanced or metastatic urethroid skin cancer (mUC), specifically: (1) patients with progression during or after platinum chemotherapy; JAVELIN Bladder 100 is a validated Phase III study based on the results of which the FDA has changed Bavencio's treatment of UC adaptation from accelerated approval to full approval.
-
2020 ESMO: For the first time, parp inhibitor Parmipali was released as a key Phase 2 clinical trial data for the treatment of patients with advanced ovarian cancer.
Time of Update: 2020-10-06
this means that both platinum-sensitive and platinum-resistant ovarian cancer patients have shown good clinical benefits and that single-drug treatments are safe and easy to manage.
-
Clinical, imaging and molecular characteristics of myeloma.
Time of Update: 2020-10-06
(5) KIAA1549-BRAF fusion genes are the most common molecular characteristics in myelin and in the brain I.
conclusions, IMA has different clinical, imaging, and molecular characteristics than in-brain asclusive cell tumors.
-
Immunotherapy breaks the first line of treatment of esophageal cancer, and then meets the turning point of treatment.
Time of Update: 2020-10-06
Esophageal cancer, as a high-risk and high-death cancer, has made very limited progress in treatment over the past decade, and it was not until recent years that immunotherapy was approved for second-
-
CheckMate-577: Odivo aids therapy for esophageal cancer and gastric esophageal connecting cancer patients can significantly improve disease-free survival.
Time of Update: 2020-10-06
Sammons Cancer Center at Baylor University Medical Center, said, "According to the CheckMate-577 study, patients treated with Odivo's assisted treatment doubled their disease-free survival, the first breakthrough in complementary therapy in the field of esophageal cancer and gastroesophageal cancer." " is good for safety and tolerance compared to placebos.
-
Stomach cancer esophageal cancer is heavy! The combined chemotherapy first-line treatment of The hundred-time Mestrebo Opdivo significantly extends the total lifetime!
Time of Update: 2020-10-06
"CheckMate-649 is the first global study in more than a decade to demonstrate significant benefits to total survival (OS) compared to chemotherapy in patients with first-line treatments for non-HER2-positive stomach, gastroesophageal junction, or esophageal adenocarcinoma, highlighting the potential of Opdivo-chemotherapy as a new standard of care for these patients, regardless of their location," said Dr. Ian M.
-
Heavyweight: Navuliyu monotherapy first-line treatment of stomach and esophageal cancer, significantly improving the total survival and non-progression survival.
Time of Update: 2020-10-06
Compared to individual chemotherapy, Odivo (Navulyu monoanti) combined chemotherapy first-line treatment of non-removable advanced or metastatic gastric cancer, gastroesophageal connecting cancer (GEJ) or esophageal adenocarcinoma patients achieved statistically significant and clinically significant total survival (OS) and progressive survival (PFS) benefits.
-
Lung cancer is overweight! Mercadon Keytruda first-line treatment of PD-L1 high expression lung cancer: patients who completed 2 years of treatment, 5 years survival rate of 81.4%!
Time of Update: 2020-10-06
September 22, 2020 // -- Merck Co) recently presented five-year survival data for the first-line treatment of non-small cell lung cancer (NSCLC) in the key Phase III KEYNOTE-024 trial of the anti-PD-1 therapy Keytruda (Korida, generic name: pembrolizumab, Pabli pearl monoantigen) at the 2020 Virtual Conference of the European Society of Medical Oncology (ESMO).
-
Cancer "immunity and targeting" treatment! Mercadon/Weedy Keytruda and Lenvima combination therapy 7 different types of tumors show efficacy!
Time of Update: 2020-10-06
results showed that the Keytruda-Lenvima combination therapy showed efficacy in all seven types of tumors: (1) Phase 2 LEAP-004 trial, the combination therapy previously received anti-PD-1/PD-L1 therapy of non-removable or metastasis melanoma patients objective remission rate (ORR) was 21.4%.
-
Esophageal cancer is making great progress! Mercadon Keytruda (Corida) and chemotherapy first-line treatment phase 3 clinical: reduce the risk of death by 27%!
Time of Update: 2020-10-06
currently, Keytruda has been approved in the United States, China, and Japan as a single-drug therapy for patients with relapsed localized advanced or metastatic esophageal squamous cell carcinoma with a second-line treatment tumor expression PD-L1 (combined positive score (CPS) of 10).
-
Advanced kidney cancer "immune and targeted" first-line treatment! BMS/ Exelixis combination therapy Opdivo and Cabometyx show significant survival benefits!
Time of Update: 2020-10-06
!-- Webeditor: page title-- September 21, 2020 // -- BMS and partner Exelixis recently unveiled the anti-PD-1 Therapy Opdivo (Odivo, generic name: nivolumab, navuliyu monoanti) combined to target the anti-cancer drug Cabometyx (cabozantinib, cabodinib) first-line treatment of advanced renal cell carcinoma (RCC) key Phase III CheckMate-9ER trial results.
-
2020 ESMO: Infineon has a major breakthrough in the treatment of stage III non-small cell lung cancer, and about 50% of patients have a four-year survival period
Time of Update: 2020-10-06
!-- updated results of the Phase III PACEIFIC clinical trial show that AstraZeneve's Infinfan (chemical name: Duvalumab, product name: Infinfan Imfinzi) In patients with non-removable non-small cell lung cancer (NSCLC) who did not show disease progression after receiving synchrotron chemotherapy (CRT), the benefits of continuous and clinically significant total survival (OS) and disease-free progression survival (PFS) were shown.
-
CAR-T targeting B7-H3 inhibits glioblastoma stem cells.
Time of Update: 2020-10-06
The authors then verified the anti-tumor activity of B7-H3 reprogrammed CAR-T cells in GBM cell line and GBM nerve tumor spheres from patients in in vitro and in vivo heterogeneity transplant mouse model trials, the results of which were published in the September 2019 issue of EBioMedicine.
-
New first-line treatment for lung cancer (NSCLC)! BMS star immunology combination Opdivo and Yervoy plus limited chemotherapy approved by THECHMP!
Time of Update: 2020-10-06
September 21, 2020 // -- The European Medicines Agency (EMA) Commission on Human Pharmaceutical Products (CHMP) has issued an active review recommending approval of the anti-PD-1 therapy Opdivo (Odivo, generic name): nivolumab, navuliyu monoantigen) in combination with Yervoy (ipilimumab, Iplimma) and 2 cycles of platinum-containing chemotherapy, first-line treatment of tumors without sensitivity to EGFR mutation or ALC subpopulation metastasis of metastasis non-small cell lung cancer (NSCLC) adult patients.
